SRX Antibody

What is Sulfiredoxin (SRX) and why are antibodies against it important in research?

Sulfiredoxin (SRX) is a protein that plays a critical role in protecting host cells from oxidative damage primarily by reducing hyperoxidized peroxiredoxins. Recent evidence suggests that beyond its antioxidant function, SRX may also influence tumorigenesis and metastasis in various cancers . Antibodies against SRX are important research tools for studying its expression, localization, and interactions with other proteins in various biological contexts. They enable researchers to investigate the dual nature of SRX - its protective role against oxidative stress and its potential contributions to cancer progression through pathways such as AP-1/MMP9, MAPK, and Wnt/β-catenin signaling .

What types of SRX antibodies are available for research applications?

Research-grade SRX antibodies typically include:

• Monoclonal antibodies: Offer high specificity for particular epitopes of Sulfiredoxin

• Polyclonal antibodies: Recognize multiple epitopes, providing stronger signals in certain applications

• Recombinant antibodies: Engineered for specific research needs with consistent quality

• Tagged antibodies: Conjugated with fluorophores, enzymes, or other detection systems

These antibodies are validated for various research techniques including Western blotting, immunoprecipitation, immunohistochemistry, and ELISA. As demonstrated in studies investigating SRX-Peroxiredoxin interactions, anti-SRX antibodies can effectively pull down SRX-Prx complexes to study their biochemical properties and interactions .

How is SRX expression regulated in normal versus disease states?

The CRL3Keap1 E3 ligase complex plays a critical role in controlling SRX levels through ubiquitin-mediated proteasomal degradation. When this pathway is inhibited (for example, by MLN4924 treatment or knockdown of neddylation enzymes), SRX protein accumulates significantly - up to 7.5-fold in some experiments . This mechanism appears to be part of a regulatory axis where Keap1 acts as a negative regulator of the AP-1/MMP9 pathway and colorectal cancer progression through promoting SRX degradation .

What are the optimal conditions for using SRX antibodies in immunoprecipitation studies?

When using SRX antibodies for immunoprecipitation (IP) studies, researchers should consider the following optimization strategies:

• Buffer composition: Use buffers containing 20 mM HEPES (pH 7.5), 150 mM NaCl with reducing agents such as 5 mM DTT and 100 μM TCEP to maintain protein stability and interaction capabilities .

• Blocking conditions: Include 0.1% BSA in binding buffers to reduce non-specific interactions.

• Detergent selection: Low concentrations of mild detergents (0.005% Tween-20) can improve specificity without disrupting protein-protein interactions .

• Validation controls: When studying interactions with peroxiredoxins, it's critical to include controls for oxidation states, as the interaction dynamics between SRX and its target proteins are redox-sensitive.

In research examining SRX interactions with peroxiredoxins, anti-SRX antibodies successfully pulled down different SRX-Prx complexes, demonstrating that SRX interacts with various peroxiredoxins at different basal levels, primarily with Prx1 and Prx2 .

How should researchers optimize Western blot protocols for SRX detection?

For optimal detection of SRX in Western blot applications, consider these methodological adjustments:

• Sample preparation: Cell lysis should be performed under reducing conditions to preserve SRX structure. When studying SRX degradation, including proteasome inhibitors in certain experimental groups can help confirm ubiquitin-mediated degradation pathways.

• Loading controls: Since SRX expression can be dramatically affected by oxidative stress conditions, appropriate loading controls are essential. Cycloheximide (CHX) chase experiments can effectively demonstrate SRX turnover rates .

• Antibody selection and dilution: Primary anti-SRX antibody concentrations may need optimization depending on expression levels in your model system. Studies have shown that SRX protein levels vary significantly between different cell types and can increase dramatically (up to 7.5-fold) under certain conditions such as MLN4924 treatment .

• Detection method: Enhanced chemiluminescence systems provide sensitive detection of SRX, which is particularly important when studying its degradation kinetics as seen in experiments with ubiquitin-proteasome pathway inhibitors .

• Transfer optimization: Due to the relatively small size of SRX protein, optimizing transfer conditions (time, voltage, buffer composition) is crucial for efficient transfer to membranes.

What are the key considerations for using SRX antibodies in immunohistochemistry (IHC)?

Effective use of SRX antibodies in IHC requires attention to these critical factors:

• Fixation protocol: Optimal fixation methods preserve SRX epitopes while maintaining tissue architecture. Formalin-fixed paraffin-embedded (FFPE) tissues have been successfully used for SRX detection in tumor nodules from in vivo experiments .

• Antigen retrieval: Heat-induced epitope retrieval methods may be necessary to expose SRX epitopes after fixation.

• Antibody validation: Confirm antibody specificity using appropriate positive and negative controls. For instance, comparing SRX expression in tissues with Keap1 knockdown (which increases SRX levels) versus tissues with simultaneous SRX knockdown provides excellent validation controls .

• Signal interpretation: When examining SRX expression in tumor tissues, consider heterogeneity of expression patterns. IHC assays have demonstrated that downregulation of Keap1 results in notable elevation of SRX expression in lung tumor nodules, which can be rescued by simultaneous SRX knockdown .

• Quantification methods: Standardized scoring systems should be employed for semi-quantitative analysis of SRX expression levels across different tissue samples.

How can SRX antibodies be utilized to investigate protein-protein interactions using Surface Plasmon Resonance (SPR)?

Surface Plasmon Resonance (SPR) provides valuable kinetic information about SRX interactions with binding partners. When designing SPR experiments with SRX antibodies:

• Immobilization strategy: GLC sensor chips using amine coupling methods have been successfully employed for immobilizing peroxiredoxin proteins as ligands when studying their interactions with SRX .

• Buffer optimization: SPR assays for SRX interactions benefit from specific buffer compositions including 20 mM HEPES (pH 7.5), 150 mM NaCl, 5 mM DTT, 100 μM TCEP, 0.005% Tween-20, 0.1% BSA, and 5 mg/ml dextran .

• Analyte concentration series: Using multiple concentrations of purified recombinant SRX as the analyte allows for accurate determination of binding kinetics and affinity constants.

• Data analysis: The Langmuir 1:1 evaluation model has been effectively applied to analyze SRX binding data, though more complex models may be necessary depending on the specific interaction being studied .

• Mutant comparisons: SPR is particularly valuable for comparing binding kinetics between wildtype and mutant proteins, providing mechanistic insights into SRX interactions with its partners .

What strategies should be employed when using SRX antibodies to investigate the ubiquitin-proteasome degradation pathway?

Investigating SRX degradation via the ubiquitin-proteasome pathway requires sophisticated experimental approaches:

• Neddylation pathway inhibition: MLN4924 treatment can effectively block Cullin-RING E3 ligase activity, leading to significant SRX accumulation (up to 7.5-fold) in a dose- and time-dependent manner across multiple cell lines .

• Genetic validation: Knockdown of key neddylation enzymes (NAE1, UBA3, UBC12) confirms the role of CRL E3 ligases in SRX degradation, eliminating potential off-target effects of pharmacological inhibitors .

• Protein turnover analysis: Cycloheximide (CHX) chase assays combined with Western blotting using anti-SRX antibodies can precisely measure SRX protein half-life under various conditions. This approach has demonstrated that neddylation inhibition dramatically delays SRX turnover and extends its half-life .

• Ubiquitination detection: Immunoprecipitation with SRX antibodies followed by ubiquitin blotting can directly demonstrate ubiquitin modification of SRX protein.

• E3 ligase identification: Co-immunoprecipitation experiments using SRX antibodies have identified CRL3Keap1 as the specific E3 ligase complex responsible for SRX ubiquitination and degradation .

How can SRX antibodies contribute to understanding cancer progression mechanisms?

SRX antibodies are powerful tools for investigating the complex roles of SRX in cancer:

• Subcellular localization studies: Immunofluorescence using anti-SRX antibodies can track changes in SRX localization during cancer progression and in response to oxidative stress.

• Tumor model validation: In vivo experiments utilizing SRX antibodies for immunohistochemistry have confirmed that Keap1 knockdown increases SRX expression in tumor tissues, driving colorectal cancer progression .

• Metastasis investigation: SRX antibodies have helped demonstrate that the Keap1-SRX axis influences metastatic potential, with Keap1 knockdown increasing lung metastatic nodules, a phenotype reversed by simultaneous SRX depletion .

• Signaling pathway analysis: Combined with antibodies against pathway components, SRX antibodies help elucidate the mechanistic connections between SRX and oncogenic signaling cascades such as AP-1/MMP9, MAPK, and Wnt/β-catenin pathways .

• Patient sample correlation: IHC with SRX antibodies on patient-derived samples can correlate expression levels with clinical outcomes, supporting the prognostic value of SRX in certain cancer types.

How should researchers address inconsistent results when using SRX antibodies across different experimental systems?

When encountering variability in SRX antibody performance:

• Cell/tissue-specific expression patterns: SRX expression varies significantly between tissue types and cellular contexts. For example, studies have shown differential expression and interactions between SRX and various peroxiredoxin isoforms, primarily with Prx1 and Prx2 .

• Redox state influence: SRX function and detectability are highly influenced by the cellular redox environment. Experiments involving oxidative stress should include appropriate controls for altered redox states.

• Post-translational modifications: SRX undergoes various modifications including ubiquitination that can affect antibody recognition. The CRL3Keap1 E3 ligase has been identified as responsible for SRX ubiquitination, leading to its proteasomal degradation .

• Antibody validation: Each new lot of SRX antibody should be validated using positive and negative controls. Knockdown or knockout of SRX provides the most stringent specificity control, as demonstrated in studies using simultaneous SRX knockdown to validate Keap1-mediated effects .

• Cross-reactivity assessment: Some antibodies may cross-react with related proteins. Careful antibody selection and validation against recombinant protein standards can mitigate this issue.

What technical considerations are important when designing in vivo experiments utilizing SRX antibodies?

In vivo experiments with SRX antibodies require careful planning:

• Model selection: Different mouse models have been successfully employed for SRX research, including subcutaneous-transplantation tumor models, experimental lung metastasis models, and orthotopic transplantation models with bioluminescence imaging .

• Tissue processing: Standardized protocols for tissue collection, fixation, and processing are essential for consistent antibody performance in immunohistochemistry applications.

• Quantification methods: When analyzing IHC data from tumor nodules, standardized scoring systems should be employed to quantify SRX expression across treatment groups .

• Control groups design: Essential controls include comparisons between Keap1 knockdown, SRX knockdown, and double knockdown groups to establish the Keap1-SRX regulatory axis in cancer progression .

• Clinical correlation: Findings from mouse models should be correlated with human patient data whenever possible to establish translational relevance.